The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial
Open Access
- 24 March 2010
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 12 (4), 338-347
- https://doi.org/10.1093/eurjhf/hfp206
Abstract
Aims Though various neurohormonal systems are concurrently activated during heart failure (HF), their biological effectors are not always easy to measure due to their short life in vivo, instability in biological samples, or very low concentrations. We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome. Methods and results This study was performed in 1237 patients with chronic and stable HF enrolled in the GISSI‐heart failure trial (GISSI‐HF). The following four precursor fragments, mid‐regional pro‐atrial natriuretic peptide (MR‐proANP), mid‐regional pro‐adrenomedullin (MR‐proADM), C‐terminal pro‐endothelin‐1 (CT‐proET‐1) and C‐terminal pro‐vasopressin (CT‐proAVP or copeptin), were measured at randomization and after 3 months. Baseline concentrations were independent predictors of clinical outcome (median follow‐up 3.9 years). The addition of MR‐proANP improved net reclassification for mortality when added to multivariable models based on clinical risk factors alone [net reclassification improvement (NRI) = 0.12, P = 0.0007] or together with NT‐proBNP (NRI = 0.06, P = 0.01). Changes in MR‐proANP concentrations were related to mortality [HR (95% CI) 1.38 (0.99–1.93), P = 0.0614 and 1.58 (1.13–2.21), P = 0.0078 in the middle and highest vs. lowest tertiles], while changes in the other markers were not. Conclusion In patients with chronic and stable HF enrolled in a multicentre, randomized, clinical trial, measurement of stable precursor fragments of vasoactive peptides provided prognostic information independent of natriuretic peptides which are currently the best biomarkers for risk stratification.This publication has 45 references indexed in Scilit:
- Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failureClinica Chimica Acta; International Journal of Clinical Chemistry, 2009
- Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart FailureClinical Chemistry, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)Journal of the American College of Cardiology, 2008
- Outpatient Monitoring and Treatment of Chronic Heart Failure Guided by Amino-Terminal Pro–B-Type Natriuretic Peptide MeasurementThe American Journal of Cardiology, 2008
- Amino-Terminal Pro–B-Type Natriuretic Peptides and Prognosis in Chronic Heart FailureThe American Journal of Cardiology, 2008
- C-terminal pro–endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) StudyAmerican Heart Journal, 2007
- Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human PlasmaClinical Chemistry, 2006
- The Seattle Heart Failure ModelCirculation, 2006